Abstract
Background The gut microbiome and its metabolites can impact brain health and are altered in Parkinson’s disease (PD) patients. It has been recently demonstrated that PD patients have reduced fecal levels of the potent epigenetic modulator butyrate and its bacterial producers. Here, we investigate whether the changes in the gut microbiome and associated metabolites are linked to PD symptoms and epigenetic markers in leucocytes and neurons.
Methods Stool, whole blood samples, and clinical data were collected from 55 PD patients and 55 controls. We performed DNA methylation analysis on whole blood samples and analyzed the results in relation to fecal short-chain fatty acid concentrations and microbiota composition. In another cohort, prefrontal cortex neurons were isolated from control and PD brains. We identified the genome-wide DNA methylation by targeted bisulfite sequencing.
Results We show that lower fecal butyrate and reduced Roseburia, Romboutsia, and Prevotella counts are linked to depressive symptoms in PD patients. Genes containing butyrate-associated methylation sites include PD risk genes and significantly overlap with sites epigenetically altered in PD blood leucocytes, predominantly neutrophils, and in brain neurons, relative to controls. Moreover, butyrate-associated methylated-DNA (mDNA) regions in PD overlap with those altered in gastrointestinal, autoimmune, and psychiatric diseases.
Conclusions Decreased levels of bacterially produced butyrate are linked to epigenetic changes in leucocytes and neurons from PD patients, and to the severity of their depressive symptoms. PD shares common butyrate-dependent epigenetic changes with certain gastrointestinal and psychiatric disorders, which could be relevant for their epidemiological linkage.
Competing Interest Statement
PB has received commercial support as a consultant from Axial Therapeutics, Calico, CuraSen, Fujifilm-Cellular Dynamics Inc., IOS Press Partners, LifeSci Capital LLC, Lundbeck A/S, Idorsia and Living Cell Technologies LTD. He has received commercial support for grants/research from Lundbeck A/S and Roche. He has ownership interests in Acousort AB and Axial Therapeutics. S.G. receives commercial support as a consultant from Coleman Research and Biogen.
VTEA, PABP, LP, PA and FS have patents issued (FI127671B & US10139408B2) and pending (US16/186,663 & EP3149205) that are assigned to NeuroBiome Ltd.
FS is founder and CEO of NeuroInnovation Oy and NeuroBiome Ltd., is a member of the scientific advisory board and has received consulting fees and stock options from Axial Biotherapeutics.
MGT is an advisor to INmune Bio, Longevity Biotech, Prevail Therapeutics, and Weston Garfield Foundation. MGT has patents issued (US Pat. Nos. 7144987B1 and 7244823B2) and pending (US20150239951, WO2019067789, 62/901698, see efiling Ack37193677, 62/905747, see efilingAck37274773) for co-invention of DN-TNFs.
Funding Statement
This work was supported by a Farmer Family Foundation grant award and a Gibby & Friends vs. Parky Award to PB, with LB, JAP, and VL. FS received funding from the Michael J. Fox Foundation for Parkinson’s Research, the Academy of Finland (295724, 310835), the Hospital District of Helsinki and Uusimaa (UAK1014004, UAK1014005, TYH2018224), the Finnish Medical Foundation, and the Finnish Parkinson Foundation
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was conducted according to the guidelines of the Declaration of Helsinki and approved by the ethics committees of the Van Andel Research Institute and the Hospital District of Helsinki and Uusimaa. All participants gave written informed consent.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵* Filip Scheperjans and Viviane Labrie should be considered joint senior author.
Data Availability
Microbiota data are available at the European Nucleotide Archive (accession number PRJEB27564) (https://www.ebi.ac.uk/ena/browser/view/PRJEB27564). Other data and files utilized in this study are available from the corresponding authors upon reasonable request.
List of abbreviations
- PD
- Parkinson’s disease
- SCFAs
- Short-chain fatty acids
- BMI
- Body mass index
- TCA
- Tensor composition analysis
- LD
- linkage disequilibrium
- UPDRS
- Unified Parkinson’s Disease Rating Scale
- NMSQ
- Non-Motor Symptoms Questionnaire
- NMSS
- Non-Motor Symptoms Scale
- GDS-15
- Geriatric Depression Scale
- GSEA
- Gene set enrichment analysis
